Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preservative-free tafluprost + timolol fixed-dose combination versus tafluprost or timolol monotherapy in open-angle glaucoma or ocular hypertension
NL-OMON36690Phase 3Active, not recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafluprost, timolol and tafluprost + timolol in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change from baseline in average diurnal intraocular pressure at 3 months. Started Jun 2011; status: active, not recruiting.
02
Drugs
tafluprosttimololtafluprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NL-OMON36690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36690.